IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale IMX-110 + anti-PD-1 ...
(RTTNews) - Immix Biopharma, Inc. (IMMX) shares are soaring more than 25 percent on Wednesday morning trade after the company reported a positive response for its lead candidate IMX -110 in first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results